J Korean Med Sci.  2011 Nov;26(11):1415-1420. 10.3346/jkms.2011.26.11.1415.

Different Clinical Characteristics Among Aeromonas hydrophila, Aeromonas veronii biovar sobria and Aeromonas caviae Monomicrobial Bacteremia

Affiliations
  • 1Division of Infectious Disease, Department of Medicine, Buddhist Taipei Tzu Chi General Hospital, Taipei, Taiwan.
  • 2Division of Infectious Disease, Department of Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
  • 3Division of Infectious Disease, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital, Hualien, Taiwan. antibody_1@msn.com
  • 4School of Medicine, Tzu Chi University, Hualien, Taiwan.

Abstract

This study aimed to compare the clinical presentations of Aeromonas hydrophila, A. veronii biovar sobria and A. caviae monomicrobial bacteremia by a retrospective method at three hospitals in Taiwan during an 8-yr period. There were 87 patients with A. hydrophila bacteremia, 45 with A. veronii biovar sobria bacteremia and 22 with A. caviae bacteremia. Compared with A. hydrophila and A. veronii biovar sobria bacteremia, A. caviae bacteremia was more healthcare-associated (45 vs 30 and 16%; P = 0.031). The patients with A. caviae bacteremias were less likely to have liver cirrhosis (27 vs 62 and 64%; P = 0.007) and severe complications such as shock (9 vs 40 and 47%; P = 0.009) and thrombocytopenia (45 vs 67 and 87%; P = 0.002). The APACHE II score was the most important risk factor of Aeromonas bacteremia-associated mortalities. The APACHE II scores of A. caviae bacteremias were lower than A. hydrophila bacteremia and A. veronii biovar sobria bacteremia (7 vs 14 and 16 points; P = 0.002). In conclusion, the clinical presentation of A. caviae bacteremia was much different from A. hydrophila and A. veronii biovar sobria bacteremia. The severity and mortality of A. caviae bacteremia were lower than A. hydrophila or A. veronii biovar sobria bacteremia.

Keyword

Aeromonas hydrophilia; Aeromonas veronii biovar sobria; Aeromonas caviae; Bacteremia

MeSH Terms

APACHE
Adult
Aeromonas caviae/drug effects/*pathogenicity
Aeromonas hydrophila/drug effects/*pathogenicity
Aged
Aged, 80 and over
Bacteremia/complications/drug therapy/*microbiology/mortality
Cross Infection/microbiology
Female
Gram-Negative Bacterial Infections/complications/drug therapy/*microbiology/mortality
Humans
Liver Cirrhosis/microbiology
Male
Middle Aged
Retrospective Studies
Shock, Septic/microbiology
Taiwan
Thrombocytopenia/complications
Young Adult

Figure

  • Fig. 1 Box plots of Acute Physiology and Chronic Health Evaluation II (APACHE II) scores distributions for A. hydrophila, A. veronii biovar sobria, and A. caviae bacteremia (A) and box plots of APACHE II scores distributions for survivals and deaths in different Aeromonas groups (B).


Reference

1. Hazen TC, Fliermans CB, Hirsch RP, Esch GW. Prevalence and distribution of Aeromonas hydrophila in the United States. Appl Environ Microbiol. 1978. 36:731–738.
2. Ko WC, Lee HC, Chuang YC, Liu CC, Wu JJ. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect. 2000. 40:267–273.
3. Lay CJ, Zhuang HJ, Ho YH, Tsai YS, Wang LS, Tsai CC. Different clinical characteristics between polymicrobial and monomicrobial Aeromonas bacteremia: study of 216 cases. Intern Med. 2010. 49:2415–2421.
4. Kang JM, Kim BN, Choi SH, Kim NJ, Woo JH, Ryu J, Kim YS. Clinical features and prognostic factors of Aeromonas bacteremia. Infect Chemother. 2005. 37:161–166.
5. Sherlock CH, Burdge DR, Smith JA. Does Aeromonas hydrophila preferentially colonize the bowels of patients with hematologic malignancies? Diagn Microbiol Infect Dis. 1987. 7:63–68.
6. Krzymińska S, Kaznowski A, Lindner K, Mnichowska M. Enteropathogenic activity and invasion of HEp-2 cells by Aeromonas caviae clinical isolates. Acta Microbiol Pol. 2003. 52:277–283.
7. Laohachai KN, Bahadi R, Hardo MB, Hardo PG, Kourie JI. The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea. Toxicon. 2003. 42:687–707.
8. Janda JM. Biochemical and exoenzymatic properties of Aeromonas species. Diagn Microbiol Infect Dis. 1985. 3:223–232.
9. Dryden M, Munro R. Aeromonas septicemia: relationship of species and clinical features. Pathology. 1989. 21:111–114.
10. Motyl MR, McKinley G, Janda JM. In vitro susceptibilities of Aeromonas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimicrobial agents. Antimicrob Agents Chemother. 1985. 28:151–153.
11. Burgos A, Quindós G, Martínez R, Rojo P, Cisterna R. In vitro susceptibility of Aeromonas caviae, Aeromonas hydrophila and Aeromonas sobria to fifteen antibacterial agents. Eur J Clin Microbiol Infect Dis. 1990. 9:413–417.
12. Wu CJ, Wu JJ, Yan JJ, Lee HC, Lee NY, Chang CM, Shih HI, Wu HM, Wang LR, Ko WC. Clinical significance and distribution of putative virulence markers of 116 consecutive clinical Aeromonas isolates in southern Taiwan. J Infect. 2007. 54:151–158.
13. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Document M45-A. 2006. Wayne, PA: Clinical and Laboratory Standards Institute.
14. Abbott SL, Cheung WK, Janda JM. The genus Aeromonas: biochemical characteristics, atypical reactions, and phenotypic identification schemes. J Clin Microbiol. 2003. 41:2348–2357.
15. Ormen O, Granum PE, Lassen J, Figueras MJ. Lack of agreement between biochemical and genetic identification of Aeromonas spp. APMIS. 2005. 113:203–207.
16. Lamy B, Laurent F, Verdier I, Decousser JW, Lecaillon E, Marchandin H, Roger F, Tigaud S, de Montclos H, Kodjo A. colBVH Study Group. Accuracy of 6 commercial systems for identifying clinical Aeromonas isolates. Diagn Microbiol Infect Dis. 2010. 67:9–14.
17. Duthie R, Ling TW, Cheng AF, French GL. Aeromonas septicaemia in Hong Kong species distribution and associated disease. J Infect. 1995. 30:241–244.
18. Janda JM, Guthertz LS, Kokka RP, Shimada T. Aeromonas species in septicemia: laboratory characteristics and clinical observations. Clin Infect Dis. 1994. 19:77–83.
19. Funada H, Matsuda T. Aeromonas bacteremia in patients with hematologic diseases. Intern Med. 1997. 36:171–174.
20. Harris RL, Fainstein V, Elting L, Hopfer RL, Bodey GP. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis. 1985. 7:314–320.
21. Lee LN, Luh KT, Hsieh WC. Bacteremia due to Aeromonas hydrophila: a report of 40 episodes. Taiwan Yi Xue Hui Za Zhi. 1986. 85:123–132.
22. Ko WC, Chuang YC. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis. 1995. 20:1298–1304.
23. Lye DJ, Rodgers MR, Stelma G, Vesper SJ, Hayes SL. Characterization of Aeromonas virulence using an immunocompromised mouse model. Curr Microbiol. 2007. 54:195–198.
24. Yucel N, Erdogan S. Virulence properties and characterization of aeromonads isolated from foods of animal origin and environmental sources. J Food Prot. 2010. 73:855–860.
25. Galindo CL, Fadl AA, Sha J, Gutierrez C Jr, Popov VL, Boldogh I, Aggarwal BB, Chopra AK. Aeromonas hydrophila cytotoxic enterotoxin activates mitogen-activated protein kinases and induces apoptosis in murine macrophages and human intestinal epithelial cells. J Biol Chem. 2004. 279:37597–37612.
26. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology. 1995. 108:1835–1841.
27. Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci. 1996. 41:557–561.
28. Such J, Guardiola JV, de Juan J, Casellas JA, Pascual S, Aparicio JR, Solá-Vera J, Pérez-Mateo M. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002. 14:371–376.
29. Chiva M, Guarner C, Peralta C, Llovet T, Gómez G, Soriano G, Balanzó J. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol. 2003. 15:145–150.
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr